All In Biotech

Drug Trial Radar · NCT01831765

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

Last checked: Nov 19, 2026Latest source record: Jun 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,290 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,290

Actual

Start

Aug 26, 2013

Primary completion

May 12, 2015

Study completion Jun 11, 2015

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Apr 15, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of FIAsp (faster-acting insulin aspart) compared to insulin aspart, both in combination with insulin detemir in adults with type 1 diabetes. This trial consists of two periods: a 26 week treatment period followed by a 26 week additional treatment period.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 1

Interventions

  • Faster-acting insulin aspartDrug

    Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.

  • insulin detemirDrug

    Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.

  • insulin aspartDrug

    Injected subcutaneously (s.c., under the skin), dose individually adjusted.

  • Faster-acting insulin aspartDrug

    Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal time dosing is defined as injecting 20 minutes after the start of the meal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in HbA1c (Glycosylated Haemoglobin)Time frame: Week 0, week 26

Locations

191 sites in 9 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Mobile, Alabama

  • Novo Nordisk Investigational Site

    Tucson, Arizona

  • Novo Nordisk Investigational Site

    Tucson, Arizona

  • Novo Nordisk Investigational Site

    Anaheim, California

  • Novo Nordisk Investigational Site

    Concord, California

  • Novo Nordisk Investigational Site

    Escondido, California

  • Novo Nordisk Investigational Site

    Fresno, California

  • Novo Nordisk Investigational Site

    Fullerton, California

  • Novo Nordisk Investigational Site

    Inglewood, California

  • Novo Nordisk Investigational Site

    La Jolla, California

  • Novo Nordisk Investigational Site

    La Mesa, California

  • Novo Nordisk Investigational Site

    Long Beach, California

  • Novo Nordisk Investigational Site

    North Hollywood, California

  • Novo Nordisk Investigational Site

    Northridge, California

  • Novo Nordisk Investigational Site

    Poway, California

  • Novo Nordisk Investigational Site

    San Diego, California

  • Novo Nordisk Investigational Site

    Santa Barbara, California

  • Novo Nordisk Investigational Site

    Santa Barbara, California

  • Novo Nordisk Investigational Site

    Ventura, California

  • Novo Nordisk Investigational Site

    Ventura, California

  • Novo Nordisk Investigational Site

    Walnut Creek, California

  • Novo Nordisk Investigational Site

    Denver, Colorado

  • Novo Nordisk Investigational Site

    Newark, Delaware

  • Novo Nordisk Investigational Site

    Boca Raton, Florida

  • Novo Nordisk Investigational Site

    Coral Gables, Florida

  • Novo Nordisk Investigational Site

    Fleming Island, Florida

  • Novo Nordisk Investigational Site

    Fort Lauderdale, Florida

  • Novo Nordisk Investigational Site

    Fort Lauderdale, Florida

  • Novo Nordisk Investigational Site

    Jacksonville, Florida

  • Novo Nordisk Investigational Site

    Miami, Florida

  • Novo Nordisk Investigational Site

    Miami, Florida

  • Novo Nordisk Investigational Site

    Miami, Florida

  • Novo Nordisk Investigational Site

    Miami, Florida

  • Novo Nordisk Investigational Site

    Miami, Florida

  • Novo Nordisk Investigational Site

    Sanford, Florida

  • Novo Nordisk Investigational Site

    Tampa, Florida

  • Novo Nordisk Investigational Site

    Atlanta, Georgia

  • Novo Nordisk Investigational Site

    Atlanta, Georgia

  • Novo Nordisk Investigational Site

    Dunwoody, Georgia

  • Novo Nordisk Investigational Site

    Lawrenceville, Georgia

Showing 40 of 191 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.